Soligenix Inc.

NASDAQ:SNGX USA Biotechnology
Market Cap
$12.41 Million
Market Cap Rank
#27811 Global
#9303 in USA
Share Price
$1.23
Change (1 day)
+0.00%
52-Week Range
$1.04 - $4.96
All Time High
$3216.00
Categories
Companies in USA Biotechnology
About

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the tre… Read more

Soligenix Inc. (SNGX) - Net Assets

Latest net assets as of September 2025: $7.60 Million USD

Based on the latest financial reports, Soligenix Inc. (SNGX) has net assets worth $7.60 Million USD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.29 Million) and total liabilities ($3.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $7.60 Million
% of Total Assets 67.27%
Annual Growth Rate 3.85%
5-Year Change 10.06%
10-Year Change N/A
Growth Volatility 333.58

Soligenix Inc. - Net Assets Trend (1995–2024)

This chart illustrates how Soligenix Inc.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Soligenix Inc. (1995–2024)

The table below shows the annual net assets of Soligenix Inc. from 1995 to 2024.

Year Net Assets Change
2024-12-31 $4.12 Million +63.26%
2023-12-31 $2.52 Million +202.09%
2022-12-31 $-2.47 Million -123.04%
2021-12-31 $10.72 Million +186.56%
2020-12-31 $3.74 Million +156.79%
2019-12-31 $1.46 Million -76.80%
2018-12-31 $6.28 Million -0.63%
2017-12-31 $6.32 Million -14.57%
2016-12-31 $7.40 Million +40502.25%
2015-12-31 $-18.31K +88.10%
2014-12-31 $-153.89K +91.30%
2013-12-31 $-1.77 Million -149.84%
2012-12-31 $3.55 Million -47.71%
2011-12-31 $6.79 Million -7.70%
2010-12-31 $7.36 Million -9.99%
2009-12-31 $8.17 Million +313.44%
2008-12-31 $1.98 Million -23.67%
2007-12-31 $2.59 Million +333.69%
2006-12-31 $-1.11 Million -172.54%
2005-12-31 $1.53 Million -48.78%
2004-12-31 $2.98 Million -43.11%
2003-12-31 $5.24 Million +22.38%
2002-12-31 $4.29 Million +263.02%
2001-12-31 $-2.63 Million -124.93%
2000-12-31 $10.55 Million +45.34%
1999-12-31 $7.26 Million -50.64%
1998-12-31 $14.70 Million -20.11%
1997-12-31 $18.40 Million +1542.86%
1996-12-31 $1.12 Million -18.73%
1995-12-31 $1.38 Million --

Equity Component Analysis

This analysis shows how different components contribute to Soligenix Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 22571394900.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock $2.51K 0.06%
Other Comprehensive Income $45.79K 1.11%
Other Components $238.04 Million 5780.39%
Total Equity $4.12 Million 100.00%

Soligenix Inc. Competitors by Market Cap

The table below lists competitors of Soligenix Inc. ranked by their market capitalization.

Company Market Cap
Workhorse Group Inc
NASDAQ:WKHS
 		$11.74 Million
Lipidor Ab
ST:LIPI
 		$11.74 Million
24SevenOffice Scandinavia AB
ST:247
 		$11.74 Million
Hung Thinh Incons JSC
VN:HTN
 		$11.74 Million
Luo Lih Fen Holding Co Ltd
TW:6666
 		$11.73 Million
K Seng Seng Corporation Bhd
KLSE:5192
 		$11.73 Million
Barloworld Ltd
JSE:BAW
 		$11.72 Million
Gem Diamonds Limited
PINK:GMDMF
 		$11.72 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Soligenix Inc.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 2,522,422 to 4,118,071, a change of 1,595,649 (63.3%).
  • Net loss of 8,266,576 reduced equity.
  • New share issuances of 5,812,959 increased equity.
  • Other comprehensive income increased equity by 23,546.
  • Other factors increased equity by 4,025,720.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-8.27 Million -200.74%
Share Issuances $5.81 Million +141.16%
Other Comprehensive Income $23.55K +0.57%
Other Changes $4.03 Million +97.76%
Total Change $- 63.26%

Book Value vs Market Value Analysis

This analysis compares Soligenix Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 0.50x
  • The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
  • The price-to-book ratio has increased from 0.00x to 0.50x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1995-12-31 $815.98 $1.23 x
1997-12-31 $17574.02 $1.23 x
1998-12-31 $1898.16 $1.23 x
1999-12-31 $2024.03 $1.23 x
2000-12-31 $2595.02 $1.23 x
2001-12-31 $-586.43 $1.23 x
2002-12-31 $571.49 $1.23 x
2003-12-31 $539.20 $1.23 x
2004-12-31 $220.32 $1.23 x
2005-12-31 $92.19 $1.23 x
2006-12-31 $-52.16 $1.23 x
2007-12-31 $85.69 $1.23 x
2008-12-31 $58.22 $1.23 x
2009-12-31 $2342.86 $1.23 x
2010-12-31 $109.06 $1.23 x
2011-12-31 $92.96 $1.23 x
2012-12-31 $47.83 $1.23 x
2013-12-31 $-274.69 $1.23 x
2014-12-31 $-16.39 $1.23 x
2015-12-31 $-1.69 $1.23 x
2016-12-31 $495.40 $1.23 x
2017-12-31 $246.85 $1.23 x
2018-12-31 $114.37 $1.23 x
2019-12-31 $18.05 $1.23 x
2020-12-31 $32.67 $1.23 x
2021-12-31 $57.71 $1.23 x
2022-12-31 $-13.77 $1.23 x
2023-12-31 $5.20 $1.23 x
2024-12-31 $2.48 $1.23 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Soligenix Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -200.74%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -6925.11%
  • • Asset Turnover: 0.01x
  • • Equity Multiplier: 2.18x
  • Recent ROE (-200.74%) is below the historical average (-139.07%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1995 -86.20% 0.00% 0.00x 1.04x $-1.33 Million
1997 -17.39% -3200.00% 0.01x 1.04x $-5.04 Million
1998 -346.03% -10900.00% 0.01x 2.57x $-22.43 Million
1999 -103.37% -750100000.00% 0.00x 1.28x $-8.23 Million
2000 -45.48% -479600000.00% 0.00x 1.30x $-5.85 Million
2001 0.00% 0.00% 0.00x 0.00x $-14.37 Million
2002 -115.88% 0.00% 0.00x 1.36x $-5.39 Million
2003 -100.83% -6309.62% 0.01x 1.19x $-5.81 Million
2004 -196.81% -588.68% 0.20x 1.70x $-6.17 Million
2005 -308.89% -153.45% 0.91x 2.21x $-4.87 Million
2006 0.00% -352.92% 1.64x 0.00x $-8.05 Million
2007 -238.00% -490.06% 0.33x 1.46x $-6.42 Million
2008 -173.08% -148.14% 0.69x 1.70x $-3.62 Million
2009 -73.82% -214.28% 0.30x 1.15x $-6.85 Million
2010 -100.40% -379.21% 0.21x 1.26x $-8.12 Million
2011 -35.03% -31.05% 0.93x 1.21x $-3.06 Million
2012 -117.23% -132.37% 0.67x 1.32x $-4.52 Million
2013 0.00% -312.00% 0.39x 0.00x $-9.88 Million
2014 0.00% -95.23% 1.01x 0.00x $-6.69 Million
2015 0.00% -89.31% 1.19x 0.00x $-7.83 Million
2016 -43.87% -31.06% 1.02x 1.39x $-3.98 Million
2017 -113.09% -131.57% 0.57x 1.51x $-7.78 Million
2018 -141.72% -169.81% 0.50x 1.67x $-9.53 Million
2019 -642.05% -290.94% 0.41x 5.34x $-9.50 Million
2020 -472.72% -916.25% 0.10x 5.32x $-18.06 Million
2021 -117.05% -37632.97% 0.00x 2.51x $-13.62 Million
2022 0.00% -5519.34% 0.02x 0.00x $-13.55 Million
2023 -243.45% -731.60% 0.09x 3.88x $-6.39 Million
2024 -200.74% -6925.11% 0.01x 2.18x $-8.68 Million

Industry Comparison

This section compares Soligenix Inc.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $184,483,093
  • Average return on equity (ROE) among peers: -41.08%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Soligenix Inc. (SNGX) $7.60 Million -86.20% 0.49x $11.73 Million
Aadi Bioscience Inc (AADI) $136.41 Million -80.71% 0.16x $17.03 Million
America Great Health (AAGH) $-48.07K 0.00% 0.00x $2.12 Million
Ascentage Pharma Group International (AAPG) $408.66 Million -216.05% 5.93x $2.25 Billion
Aardvark Therapeutics, Inc. Common Stock (AARD) $-54.64 Million 0.00% 0.00x $59.51 Million
ABIVAX Société Anonyme (AAVXF) $48.18 Million -23.29% 0.12x $377.86 Million
Abcellera Biologics Inc (ABCL) $1.23 Billion 12.85% 0.25x $740.10 Million
Abeona Therapeutics Inc (ABEO) $102.55 Million -82.14% 0.47x $210.89 Million
Acumen Pharmaceuticals Inc (ABOS) $-11.42 Million 0.00% 0.00x $117.44 Million
Abpro Holdings, Inc. (ABP) $-85.14 Million 0.00% 0.00x $2.00 Million
Absci Corp (ABSI) $67.00 Million -21.42% 0.32x $316.52 Million